Axogen Inc (AXGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Axogen Inc stock (AXGN) is currently trading at $33.28. Axogen Inc PS ratio (Price-to-Sales) is 7.09. Analyst consensus price target for AXGN is $40.56. WallStSmart rates AXGN as Sell.
- AXGN PE ratio analysis and historical PE chart
- AXGN PS ratio (Price-to-Sales) history and trend
- AXGN intrinsic value — DCF, Graham Number, EPV models
- AXGN stock price prediction 2025 2026 2027 2028 2029 2030
- AXGN fair value vs current price
- AXGN insider transactions and insider buying
- Is AXGN undervalued or overvalued?
- Axogen Inc financial analysis — revenue, earnings, cash flow
- AXGN Piotroski F-Score and Altman Z-Score
- AXGN analyst price target and Smart Rating
Axogen Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Axogen Inc (AXGN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Axogen Inc (AXGN) Key Strengths (2)
85.44% of shares held by major funds and institutions
Strong revenue growth at 21.30% annually
Supporting Valuation Data
Axogen Inc (AXGN) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Very expensive at 12.4x book value
Premium valuation at 7.1x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Axogen Inc (AXGN) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Revenue Growth. Growth metrics are encouraging with Revenue Growth at 21.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including PEG Ratio (99.04), Price/Sales (7.09), Price/Book (12.40) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -13.50%, Operating Margin at -16.30%, Profit Margin at -6.97%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -13.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 21.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AXGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AXGN's Price-to-Sales ratio of 7.09x trades at a deep discount to its historical average of 510.61x (5th percentile). The current valuation is 100% below its historical high of 3449.89x set in Feb 2009, and 12% above its historical low of 6.34x in May 2010.
WallStSmart Analysis Synopsis
Data-driven financial summary for Axogen Inc (AXGN) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Axogen Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 225M with 21% growth year-over-year. The company is currently unprofitable, posting a -7.0% profit margin.
Key Findings
Generating 2M in free cash flow and 3M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -7.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Axogen Inc maintain 21%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Axogen Inc.
Bottom Line
Axogen Inc offers an attractive blend of growth (21% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Axogen Inc(AXGN)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.